
Daily Pill May Work as Well as Ozempic for Weight Loss and Blood Sugar
A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.
The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But GLP-1s are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used.
'In the coming decades, 700 million people around the world will have Type 2 diabetes, and over a billion will have obesity,' said Dr. Daniel Skovronsky, Lilly's chief scientific officer. 'Injections cannot be the solution for billions of people around the world.'
The results Lilly announced came from a clinical trial involving 559 people with Type 2 diabetes who took the new pill or a placebo for 40 weeks. In patients who took orforglipron, blood sugar levels fell by 1.3 to 1.6 percent, about the same amount in that time period experienced by patients taking Ozempic and Mounjaro in unrelated trials. For 65 percent of people taking the new pill, blood sugar levels dropped into the normal range.
Patients on the new pill also lost weight — up to 16 pounds without reaching a plateau at the study's end. Their weight loss was similar to that achieved in 40 weeks with Ozempic but slightly less than with Mounjaro in unrelated trials.
Side effects were the same as those with the injectable obesity drugs — diarrhea, indigestion, constipation, nausea and vomiting.
This was the first of seven large clinical trials of orforglipron to report results. Some of the others are testing the drug for weight loss in people without diabetes.
The company said it would present these new results at the annual meeting of the American Diabetes Association's Scientific Sessions in June and will publish them in a peer-reviewed journal.
Lilly added that it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes.
If the drug is approved for obesity and diabetes, Dr. Skovronsky said, the company is confident it will have sufficient amounts of the pills to meet demand. He said that he had learned the results of the diabetes study on Tuesday morning but that without even knowing them, the company had been preparing supplies. It has built factories and has already made a billion pills.
Twelve percent of American adults say they have taken a GLP-1. About 40 percent of Americans are obese, and more than 10 percent have diabetes, most of whom have Type 2, according to the Centers for Disease Control and Prevention.
In a way, the very existence of orforglipron is a triumph of modern chemistry. The injectable GLP-1 drugs are peptides — small fragments of proteins. (GLP stands for glucagon-like peptide.) Peptides are digested by the stomach. So, in order to make an oral GLP-1, chemists had to find a way to make a nonpeptide that acts exactly like a peptide. Researchers at Chugai Pharmaceutical Company, a Japanese company, figured out a way, licensing their drug to Lilly in 2018.
The solution was to find a small molecule — thousandths of the size of a peptide — that sinks into a tiny pocket in the protein that is the target for GLP-1s. When it sinks into the pocket, the protein changes shape just as it does when a GLP-1 binds to the whole protein.
Finding that small molecule, Dr. Skovronsky said, was 'the holy grail.'
The result — a pill that can be taken at any time of day, with or without food — is almost unheard-of in the world of peptide drugs. Insulin, probably the most common peptide drug, has been around for more than 50 years. It is still only an injectable despite intense efforts by scientists to make an insulin pill. So is human growth hormone. So are drugs used to treat a wide variety of diseases, including arthritis and cancer.
Novo Nordisk has a GLP-1 pill, Rybelsus, but it contains the GLP-1 peptide, so it must be taken in large doses and is not as effective as the injectables because most of it is digested.
But for patients with diabetes and those struggling with obesity, a pill that can replace an injection can be transformative, for several reasons.
One is that it can make treatments attractive to those who cannot bear very idea of injecting themselves.
Dr. C. Ronald Kahn, a professor of medicine at Harvard and chief academic officer at Harvard's Joslin Diabetes Center, said he had many patients who were reluctant to inject themselves with Ozempic or Mounjaro.
A pill, he said, 'would definitely be preferred by most people.'
Dr. Sean Wharton, director of the Wharton Medical Clinic in Burlington, Ontario, has a broader hope. Dr. Wharton, who enrolled patients in Lilly's study of orforglipron for obesity, said a pill could potentially bring GLP-1 treatment to underserved populations throughout the world.
'It can be easily made in a factory and shipped everywhere,' he said. It should cost much less to make than peptides and does not require packaging in special injection pens. It does not have to be kept refrigerated.
For now, only rich countries have had access to GLP-1 drugs, and even in those countries, the drugs are available only to a small portion of people.
'Here we have a chance of a medicine being given to millions and millions of people,' Dr. Wharton said.
But that depends on Eli Lilly and how it chooses to price and distribute its drug.
'That's why I emphasize the word 'chance,'' Dr. Wharton said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
RFK Jr. Says Seed Oils Are Poison. Here's What a Dietitian Says
Seed oils have come under fire, with Health and Human Services Robert F. Kennedy, Jr., leading the charge, saying Americans are being "poisoned" by them While they can cause inflammation, Julia Zumpano, a registered dietitian with the Center for Human. Nutrition at the Cleveland Clinic says the bigger problem is that they're used in ultra-processed food The issue is less about the seed oils themselves and more about the foods they're inSeed oils — a type of processed oil found in packaged food and used for deep-frying — have come under fire, with the secretary of health and human services Robert F. Kennedy Jr. posting on X that Americans are being 'unknowingly poisoned." Wellness influencers have joined in, decrying them as the 'hateful eight": specifically, canola, corn, cottonseed, soybean, sunflower, safflower, grapeseed, and rice bran oils. The real story is a bit more complicated. 'They're not poison, but we're poisoning ourselves with everything else that's ultra-processed and processed that may be cooked in seed oils," Julia Zumpano, registered dietitian with the Center for Human Nutrition at the Cleveland Clinic, tells PEOPLE. 'The bigger picture is the fact that we're eating way too much of seed oils, which happen to be found in highly processed foods," she explains. "That's where I see the problem.' On their own, seed oils are high in Omega-6 fat, which Zumpano says is linked to increased inflammation. But, as she explains, 'instead of deep frying chicken in beef tallow versus the seed oil, let's just focus on the fact that fried chicken is not really that good for us.' Beef tallow, which Kennedy has touted as a healthier option, does have some benefits, Zumpano tells PEOPLE. 'There's nutrients in it, fat-soluble vitamins that are essential.' But when you're using it to cook highly processed foods, she explains, 'we're just flip-flopping between two issues that aren't necessarily better.' As she explains, 'We're heavily focused on the seed oils and not necessarily focused on the fact that the foods that they're in are so processed: sauces and dressings and baked goods and potato chips and candy bars and granola bars and protein bars. Even coffee creamers are loaded with seed oils,' she says. They're in highly processed food because they're more cost-effective to make, Zumpano explains: 'It's cheaper and quicker and easier to process it with chemicals and solvents.' But if you're cooking at home, she says, with 'cold pressed or hi-oleic sunflower seed oil, or a canola oil and you're drizzling it, pan-frying some fish with it, there are no health concerns like inflammation. Fast Food is a part of American culture. But that doesn't mean it has to be unhealthy, and that we can't make better choices. Did you know that McDonald's used to use beef tallow to make their fries from 1940 until phasing it out in favor of seed oils in 1990? This switch was… — Robert F. Kennedy Jr (@RobertKennedyJr) October 21, 2024 'We should just focus on really eliminating highly, ultra-processed and processed foods and going back to basics. Again, if you're gonna use the beef tallow at home to cook your eggs, fine — or the canola oil. "You're using it in moderation, a small amount, just to get the job done versus deep frying a doughnut or deep frying french fries or deep frying whatever breaded food or processed fried food you're consuming.' Ultimately, 'It's not the oil itself. It's the food that's found in the oil that is more of the problem.' If someone were to ban seed oils out of their diet, 'that's great, because they're probably cutting out a bunch of junk food," she says. "But I don't think anyone needs to be very fearful if their grandma made muffins with canola oil. They're gonna be okay if they eat that.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Read the original article on People
Yahoo
24 minutes ago
- Yahoo
Eli Lilly and Company (LLY): A Bull Case Theory
We came across a bullish thesis on Eli Lilly and Company (LLY) on Business Model Mastery's Substack. In this article, we will summarize the bulls' thesis on LLY. Eli Lilly and Company (LLY)'s share was trading at $765.68 as of 5th June. LLY's trailing and forward P/E were 62.30 and 35.09 respectively according to Yahoo Finance. A picture of a pharma technician preparing an IV injection of a biopharmaceutical product. Eli Lilly is no longer just a pharmaceutical giant—it's becoming a platform company that's reshaping the very structure of global healthcare. At the heart of this transformation is tirzepatide, a dual-action molecule marketed under separate brands for diabetes and obesity. This single drug now accounts for over a quarter of Lilly's total revenue, with the diabetes version generating $11.5 billion (up 330% YoY) and the obesity variant reaching $2.3 billion in its first year—a historic ramp-up. These are not just growth numbers; they're margin-rich results, with 85 %+ gross margins and minimal marketing spend due to entrenched trust among endocrinologists. Crucially, tirzepatide is protected by a fortress of patents through 2036 and beyond, giving Lilly a durable edge in two massive markets. Unlike peers, Lilly owns its injectable manufacturing end-to-end, having invested over $5.5 billion in internal capacity, giving it unmatched agility and control while rivals struggle with supply constraints. Its sales force and deep prescriber relationships, built over decades, have only grown more powerful thanks to a new direct-to-consumer platform that streamlines initiation and adherence. Meanwhile, the company is reinvesting aggressively, with $11 billion (24% of revenue) spent on focused R&D spanning Alzheimer's, oncology, and rare diseases. Its pipeline—anchored in metabolic, neurodegenerative, and immune disorders—builds on existing strengths, accelerating commercialization. Competition exists, but Lilly's molecule consistently outperforms, and its infrastructure outscales. With two-thirds of sales still U.S.-based, global expansion represents the next lever. In sum, Lilly's model—a convergence of science, scale, and system—positions it as more than a pharma company. It's a precision biology platform with extraordinary strategic depth and long-term compounding potential. Previously, we covered a bullish thesis on Eli Lilly (LLY) by Kontra on Substack in May 2025, which aligns with Business Model Mastery's analysis, emphasizing the company's leadership in obesity and diabetes care. Both highlight tirzepatide's explosive growth, margin strength, and Lilly's massive investment in capacity and R&D. Kontra focuses more on near-term financial results, pipeline expansion, and regulatory catalysts, while Business Model Mastery frames Lilly as a precision biology platform with structural advantages—like end-to-end manufacturing and patent longevity—that support durable outperformance. Together, they reinforce Lilly's status as a long-term compounder with deep moats and global runway. Eli Lilly and Company (LLY) is on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 119 hedge fund portfolios held LLY at the end of the first quarter which was 115 in the previous quarter. While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.


New York Times
43 minutes ago
- New York Times
Trump Budget's Caps on Grad School Loans Could Worsen Doctor Shortage
President Trump's proposed budget would make deep cuts in government health plans and medical research, and, critics say, could also make finding a doctor more difficult: It restricts loans that students rely on to pursue professional graduate degrees, making the path to becoming a physician harder even as doctor shortages loom and the American population is graying. The domestic policy bill, which passed in the House last month, would cap direct federal unsubsidized loans at $150,000 — far less than the cost of obtaining a medical education — and phase out the Grad PLUS loans that help many students make up the difference. Medicine, dentistry and osteopathic medicine are among the most expensive graduate programs. Four years of medical education costs $286,454 at a public school, on average, and $390,848 at a private one, according to the Association of American Medical Colleges. Medical school graduates leave with an average debt of $212,341, the association found. The price of a four-year program in osteopathic medicine is $297,881 at a public school, on average, and $371,403 at a private school, according to the American Association of Colleges of Osteopathic Medicine. The average indebtedness of their graduates is $259,196. The proposed loan caps 'will either push students and families into the private loan market, where they take on more risk and have less consumer protection, or simply push people out of higher education altogether,' said Aissa Canchola Bañez, policy director at the Student Borrower Protection Center, a nonprofit advocacy group. Private student loans are also not eligible for Public Service Loan Forgiveness programs, which many students rely on to manage their debt. Students from low-income families may have difficulty qualifying for private loans. Want all of The Times? Subscribe.